Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation.

@article{Maxwell2015NovelAD,
  title={Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation.},
  author={Perry Maxwell and Florinda Mel{\'e}ndez-Rodr{\'i}guez and Kyle B. Matchett and Juli{\'a}n Aragon{\'e}s and Nathalie Ben-Califa and Heidelinde Jaekel and Ludger Hengst and Herbert Lindner and Andr{\'e} Bernardini and Ulf Brockmeier and Joachim Fandrey and Fritz Grunert and Howard S Oster and Moshe Mittelman and Mohamed K El-Tanani and Markus Thiersch and Edith M Schneider Gasser and Max Gassmann and David Dangoor and Robert J G Cuthbert and Alexandra Elizabeth Irvine and Anne E Jordan and Terence R. J. Lappin and John Thompson and Drorit Neumann},
  journal={British journal of haematology},
  year={2015},
  volume={168 3},
  pages={429-42}
}
Recombinant human erythropoietin (rHuEPO) is an effective treatment for anaemia but concerns that it causes disease progression in cancer patients by activation of EPO receptors (EPOR) in tumour tissue have been controversial and have restricted its clinical use. Initial clinical studies were flawed because they used polyclonal antibodies, later shown to lack specificity for EPOR. Moreover, multiple isoforms of EPOR caused by differential splicing have been reported in cancer cell lines at the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS